HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Vigonvita Life Sciences (PHIP Updates) - Some Points Worth the Attention

Pre-IPO Three Squirrels - Pain Points of the Business Model and the Performance Outlook

Pre-IPO Genuine Biotech - The Current Pipeline Hardly Supports High Valuation

Genor Biopharma (6998 HK) - The Reverse Merger Will Unleash the Upside Potential of Valuation

Equity Capital Markets

<ul>
<li>The new payload story/ADC-engineering platforms need to be verified by big licensing-out deals. If verification is successful, MNCs will pay high price.However, if verification fails, BlissBio's pipeline would be “ignored”.</li>
<li>BlissBio entered into a wind-down agreement with Eisai for BB-1701.In our view, MNC's interest in BB-1701 is decreasing.The possibility of reaching big BD deal on BB-1712/BB-1705 is also not high.</li>
<li>The investment logic of biotech has changed and high valuation is driven by big licensing-out deals. From this perspective, we think valuation of BlissBio should be lower than peers.</li>
</ul>


The new payload story/ADC-engineering platforms need to be verified by big licensing-out deals. If verification is successful, MNCs will pay high price.However, if verification fails, BlissBio's pipeline would be “ignored”.
BlissBio entered into a wind-down agreement with Eisai for BB-1701.In our view, MNC's interest in BB-1701 is decreasing.The possibility of reaching big BD deal on BB-1712/BB-1705 is also not high.
The investment logic of biotech has changed and high valuation is driven by big licensing-out deals. From this perspective, we think valuation of BlissBio should be lower than peers.


Pre-IPO BlissBio - The Pipeline Has Not yet Been Verified as No Deal Has Been Reached with MNCs